{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:05:55Z","timestamp":1789470355747,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Alzheimer\u2019s disease (AD) is a progressive neurodegeneration and is the most prevalent form of dementia. Intervention at an early stage is imperative. Although three acetylcholinesterase inhibitors (AChEIs) are currently approved for the treatment of mild AD, they are not sufficiently effective. Novel treatments for mild AD are of utmost importance.<\/jats:p><jats:p><jats:bold>Objective:<\/jats:bold> To assess the effectiveness of hachimijiogan (HJG), a traditional Japanese herbal medicine (Kampo), in the treatment of mild AD.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This exploratory, open-label, randomized, multicenter trial enrolled patients with mild AD whose score on the Mini Mental State Examination (MMSE) was over 21points. All participants had been taking the same dosage of AChEI for more than 3\u00a0months. The participants were randomly assigned to an HJG group taking HJG extract 7.5\u00a0g\/day in addition to AChEI or to a control group treated only with AChEI. The primary outcome was the change from baseline to 6 months post treatment initiation on the Alzheimer\u2019s Disease Assessment Scale-cognitive component- Japanese version(ADAS-Jcog). The secondary outcomes were change from baseline of the Instrumental Activity of Daily Life (IADL), Apathy scale, and Neuropsychiatric Inventory (NPI) -Q score.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Among the 77 enrollees, the data of 69(34 HJG and 35 control)were available for analysis. The difference in the change of ADAS-Jcog from baseline to 6 months of the HJG and control groups was 1.29 (90% Confidence interval (CI), \u22120.74 to 3.32 <jats:italic>p<\/jats:italic> = 0.293). In the subgroup analysis, the differences in the change from baseline to 3 and 6 months for women were 3.70 (90% CI ,0.50 to 6.91, <jats:italic>p<\/jats:italic> = 0.059) and 2.90 (90% CI,0.09 to 5.71, <jats:italic>p<\/jats:italic> = 0.090), respectively. For patients over 65\u00a0years, the difference at 3\u00a0months was 2.35 (90%CI, 0.01 to 4.68 <jats:italic>p<\/jats:italic> = 0.099). No significant differences were found between the HJG and control groups in IADL score, Apathy scale, or NPI-Q score.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Although not conclusive, our data indicate that HJG has an adjuvant effect for acetylcholinesterase inhibitors and that it delays the deterioration of the cognitive dysfunction of mild Altzheimer\u2019s disease patients.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold><jats:ext-link>http:\/\/clinicaltrials.gov<\/jats:ext-link> Japan Registry of clinical trials, identifier jRCTs 071190018<\/jats:p>","DOI":"10.3389\/fphar.2022.991982","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T05:24:39Z","timestamp":1665725079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Mosaburo","family":"Kainuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Kawakatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Iritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichiro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadanori","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Hieda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Yoshiiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Hironishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Wada-Isoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Sasabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouji","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Shirafuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kajimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1590\/1980-57642020dn14-020001","article-title":"Daily functioning and dementia","volume":"14","author":"Cipriani","year":"2020","journal-title":"Dement. Neuropsychol."},{"key":"B2","volume-title":"Peripheral and central nervous system drugs advisory committee meeting","year":"1989"},{"key":"B3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease","volume":"44","author":"Farlow","year":"2000","journal-title":"Eur. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1046\/j.1365-2389.2003.51260.x","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden","volume":"51","author":"Feldman","year":"2006","journal-title":"J. Am. Geriatr. Soc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/j.1532-5415.2004.52415.x","article-title":"A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine \"ba wei di huang wan\" in the treatment of dementia","volume":"52","author":"Iwasaki","year":"2004","journal-title":"J. Am. Geriatr. Soc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.14336\/AD.2018.0328","article-title":"Traditional oriental medicines and Alzheimer's disease","volume":"10","author":"Jeon","year":"2019","journal-title":"Aging Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e22370","DOI":"10.1097\/MD.0000000000022370","article-title":"The efficacy and safety of hachimijiogan for mild alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol","volume":"99","author":"Kainuma","year":"2020","journal-title":"Med. Baltim."},{"key":"B10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fnagi.2018.00411","article-title":"Traditional Japanese herbal medicine yokukansan targets distinct but overlapping mechanisms in aged mice and in the 5xFAD mouse model of Alzheimer's disease","volume":"10","author":"Kaushik","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/ggi.13803","article-title":"Impact of loss of independence in basic activities of daily living on caregiver burden in patients with Alzheimer's disease: A retrospective cohort study.","volume":"19","author":"Kawaharada","year":"2019","journal-title":"Geriatr. Gerontol. Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3389\/fphar.2017.00850","article-title":"The traditional Japanese herbal medicine hachimijiogan elicits neurite outgrowth effects in PC12 cells and improves cognitive in AD model rats via phosphorylation of CREB","volume":"8","author":"Kubota","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/nu10121952","article-title":"Bojungikgi-tang, a traditional herbal formula, exerts neuroprotective effects and ameliorates memory impairments in Alzheimer's disease-like experimental models","volume":"10","author":"Lim","year":"2018","journal-title":"Nutrients"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S2215-0366(21)00197-8","article-title":"The need to show minimum clinically important differences in Alzheimer's disease trials","volume":"8","author":"Liu","year":"2021","journal-title":"Lancet. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/547153a","article-title":"Stop Alzheimer's before it starts","volume":"54","author":"McDade","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/tkm2.1069","article-title":"Effect of hachimijiogan on memory impairment induced by beta-amyloid combined with cerebral ischemia in rats","volume":"4","author":"Moriyama","year":"2017","journal-title":"Traditional Kampo Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of Alzheimer's disease: An analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and progress in Alzheimer's disease - FDA approval of aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jns.2015.08.024","article-title":"The burden of distress and related coping processes in family caregivers of patients with Alzheimer's disease living in the community","volume":"358","author":"Raggi","year":"2015","journal-title":"J. Neurol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/gps.2319","article-title":"The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer\u02bcs disease","volume":"25","author":"Rockwood","year":"2010","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage alzheimer disease: A randomized placebo-controlled trial","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch. Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the national institute on aging-alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1002\/gps.4788","article-title":"The association between cognitive fluctuations and activities of daily living and quality of life among institutionalized patients with dementia","volume":"33","author":"Sun","year":"2018","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1111\/j.1532-5415.2005.00512_7.x","article-title":"A Chinese herbal medicine, choto-san, improves cognitive function and activities of daily living of patients with dementia: A double-blind, randomized, placebo-controlled study","volume":"53","author":"Suzuki","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-132690","article-title":"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis","volume":"41","author":"Tan","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"B28","volume-title":"Kampo, Japanese oriental medicine","author":"Terasawa","year":"1993"},{"key":"B29","unstructured":"The Japanese 18 th edition English VersionTokyo2022"},{"key":"B30","unstructured":"Combined FDA and biogen briefing information for the november 6, 2020 meeting of the peripheral and central nervous system drugs advisory committee2020"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4086749","DOI":"10.1155\/2019\/4086749","article-title":"Kihito, a traditional Japanese Kampo medicine, improves cognitive function in Alzheimer's disease patients","volume":"2019","author":"Watari","year":"2019","journal-title":"Evid. Based. Complement. Altern. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000091790","article-title":"3-year study of donepezil therapy in Alzheimer's disease: Effects of early and continuous therapy","volume":"21","author":"Winblad","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/s0149-2918(02)80004-2","article-title":"Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness","volume":"24","author":"Wolfson","year":"2002","journal-title":"Clin. Ther."},{"key":"B34","unstructured":"2018"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.991982\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T05:24:42Z","timestamp":1665725082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.991982\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":34,"alternative-id":["10.3389\/fphar.2022.991982"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.991982","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"991982"}}